Wuhan Coronavirus Resource Thread

The Strategic Issues & International Relations Forum is a venue to discuss issues pertaining to India's security environment, her strategic outlook on global affairs and as well as the effect of international relations in the Indian Subcontinent. We request members to kindly stay within the mandate of this forum and keep their exchanges of views, on a civilised level, however vehemently any disagreement may be felt. All feedback regarding forum usage may be sent to the moderators using the Feedback Form or by clicking the Report Post Icon in any objectionable post for proper action. Please note that the views expressed by the Members and Moderators on these discussion boards are that of the individuals only and do not reflect the official policy or view of the Bharat-Rakshak.com Website. Copyright Violation is strictly prohibited and may result in revocation of your posting rights - please read the FAQ for full details. Users must also abide by the Forum Guidelines at all times.
Mort Walker
BRF Oldie
Posts: 10033
Joined: 31 May 2004 11:31
Location: The rings around Uranus.

Re: Wuhan Coronavirus Resource Thread

Post by Mort Walker »

Cyrano wrote:Distressing news of dead bodies suspected to be of covid deaths not cremated floating down the Ganga and piling up at Ghazipur and Buxar. Reportedly for lack of wood for the pyre. Bihar and UP officials blaming each other. Hindu society, organisations & administrations cant let such thing happen in 21st century, that too in the middle of this pandemic.

I'll be thankful if anyone can point me to a voluntary organisation that takes care of cremating the dead, I will donate.
RSS
Zynda
BRF Oldie
Posts: 2309
Joined: 07 Jan 2006 00:37
Location: J4

Re: Wuhan Coronavirus Resource Thread

Post by Zynda »

Question for Amber G & others who are well versed...was checking out Swasa N95 masks and they are offering 2 products.

- SWASA PLUS (for medical use)
- SWASA with Super Active Carbon Technology

Both of them seem identical in terms of overall specs but the website says the latter is recommended for Smokers & other users who are affected by bad smell/odour. My experience with reusing N95 masks tells me that my own breath smell becomes an issue after using the mask several times. This is after keeping the mask in the open for 72+ hours...So I am drawn towards the mask with activated carbon but I wonder if its gonna be suitable if I wear to an environment like a hospital etc. for vaccination purposes.

Or I can wear Venus N95 masks which are also good (& Indian) :)
Jarita
BRF Oldie
Posts: 2649
Joined: 30 Oct 2009 22:27
Location: Andromeda

Re: Wuhan Coronavirus Resource Thread

Post by Jarita »

+ 11111 Yes, spoke to some of the Sangh folks and they are looking to work on it.
Are they remarkable? The work no one else would do - except while looking for conversions, they do selflessly.

This is regarding cremations and mobile crematoriums.
Thakur_B
BRF Oldie
Posts: 2404
Joined: 11 Aug 2016 06:14

Re: Wuhan Coronavirus Resource Thread

Post by Thakur_B »

Zynda wrote:Question for Amber G & others who are well versed...was checking out Swasa N95 masks and they are offering 2 products.

- SWASA PLUS (for medical use)
- SWASA with Super Active Carbon Technology

Both of them seem identical in terms of overall specs but the website says the latter is recommended for Smokers & other users who are affected by bad smell/odour. My experience with reusing N95 masks tells me that my own breath smell becomes an issue after using the mask several times. This is after keeping the mask in the open for 72+ hours...So I am drawn towards the mask with activated carbon but I wonder if its gonna be suitable if I wear to an environment like a hospital etc. for vaccination purposes.

Or I can wear Venus N95 masks which are also good (& Indian) :)
Venus and Honeywell have ISI rated products. Would recommend.
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

Amrita masks are also very good. Available on Flipkart. Homegrown product by scientists of Amrita University. Much better breathability and filtration.

https://www.flipkart.com/amritalife-n96 ... 22717b24ad
Amrita Vishwa Vidyapeetham Scientists Launch N96 Nano Mask with 99.9% Filtration Efficiency

• The unique three-ply N96 Nano Mask based on cutting-edge nanotechnology offers very high levels of breathability on one hand and the highest possible filtration on the other – hardly any other mask in the world does so
• Costing less than Rs 200, the mask can be washed up to 30 times for reuse
• The product, based on nano-materials developed as part of a Govt. of India grant, has been tested by the South India Textile Research Association (SITRA)
• The technology is available for licensing by the varsity for volume production


Scientists of Centre for Nanosciences & Molecular Medicine at Amrita Vishwa Vidyapeetham have launched a unique three-ply N96 Nano Mask based on cutting-edge nanotechnology. It is cost effective and offers far superior filtration and breathability than the conventional N95 and surgical masks.

The Amrita N96 Nano Mask, costing less than Rs 200, can be washed up to 30 times for reuse. It is long-lasting, skin-friendly and odor-free, and provides very comfortable wear even for long durations. The fabric makes it effortless for the wearer to breathe in and out even while providing almost 100% protection against harmful microbes. Hardly any other mask in the world offers such high breathability (level 2) with maximum protection (99.9%). Amrita Vishwa Vidyapeetham is offering the technology for licensing to others for volume production and bring the cost of the mask further down.

The Amrita N96 Nano Mask with nano-layered filter is lab tested to provide 99.9% bacterial and virus aerosol filtration as well as 96% particle filtration of more than 3 microns. It has also been tested by the South India Textile Research Association (SITRA), the premier laboratory supported by the Ministry of Textiles, Government of India, to test masks and PPEs in the country.

Said Dr. Shantikumar Nair, Dean (Research) with Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham: “The Amrita N96 Nano Mask is far ahead of conventional surgical and N95 masks in providing protection to the wearer and enhancing the everyday experience with innovative nano-technology. It uses a one-of-its-kind nano-engineered filter fabricated with eletrospun biofriendly polymer nanofibers. The nano-sized channels and interconnected pores in the nano-filter cause an enhanced ‘slip effect’ which ensures low air resistance for better breathability on one hand and high filtration efficiency on the other. The specific designing of the mask also offers antifogging property. It is an ideal safety gear for healthcare workers and anyone else against infections caused by inhaling harmful bacteria and viruses.”

He added: “Some years ago, our Center at Amrita Vishwa Vidyapeetham received a grant from the Government of India to develop nano-materials for medical applications. As part of that process, we developed a unique nano-fibre-based membrane, textile and coating. Because of this experience, we were able to incorporate the textile with nano-fibre coating into a polypropylene textile that we have used to develop this nano mask.”

Explaining how the mask works, Dr. Deepthy Menon, Professor – Nanosciences, Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, said: “The Amrita N96 Nano Mask is a three-layered mask. These layers, made of cloth derived from polypropylene fiber, enclose nano-fiber membrane between them. The unique hydrophobic nature of this membrane completely blocks the passage of micro-droplets and water aerosols from one side of the layer to the other. This is what protects the wearer from breathing respiratory micro-droplets exhaled by another person and getting infected. This washable, durable and reusable mask ensures 99.9% bacterial and virus aerosol filtration.”

Dr. CR Reshmi, scientist with Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, said: “The nano-coating, though sophisticated, involves easy to use technology that is scalable and apt for industrial applications for a variety of filtration products that we are currently working on.”
Aldonkar
BRFite
Posts: 202
Joined: 27 Feb 2020 18:46

Re: Wuhan Coronavirus Resource Thread

Post by Aldonkar »

V_Raman wrote:So SII cannot produce more than 500M doses for India - 1B vials across the 2 shots? what kind of an arrangement is that? What will the produciton line do after that?
That deal was made more than a year ago when the Covid pandemic did not seem as sever as it turned out. It also had a restriction on price "while the pandemic lasts" - presumably the pandemic is declared by ,say, the WHO.

After that the quantity and price will be renegotiated.

Separately from the AZ-SII deal, there was a report in the UK press that a Pfizer executive was gleefully saying that the Coronavirus was delivering huge profits to his company and he was hoping it would be recur annually (like flu) so that they could milk the world. Sorry no link.
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

American military equipment companies pray for a war while their pharma companies pray for an epidemic
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

India conducting 18-20 lakh COVID tests a day: ICMR
India is conducting 18-20 lakh tests for detection of COVID-19 per day, the ICMR chief said on Tuesday underlining that despite infection among laboratory staff, the test performance is still being maintained.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Ivermectin: Drug that Goa recommends to all above 18 to combat Covid-19
The Goa administration on Monday cleared a new Covid-19 treatmen regime- that recommends all residents above the age of 18 to take five tablets of the ivermectin drug, in order to prevent fatal viral fever, which accompanies a Covid 19 infection. Ivermectin is an oral drug is used as a prescription medication to treat parasitic infections.
darshan
BRF Oldie
Posts: 4018
Joined: 28 Jan 2008 04:16

Re: Wuhan Coronavirus Resource Thread

Post by darshan »

No link between 5G and COVID: DoT
https://www.deshgujarat.com/2021/05/11/ ... covid-dot/
New Delhi: The telecom department asserted that there is absolutely no link between 5G technology and the spread of COVID, as it urged the public not to be misguided by baseless and false messages being circulated on social media platforms. The claim that 5G trials or networks are causing coronavirus in India is “false” and without any scientific basis, an official release said.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Today's official vaccination numbers:

COVID-19 Vaccination Update- Day 116
India’s Cumulative Vaccination Coverage exceeds 17.51 Cr doses

More than 4.7 lakh beneficiaries of age group 18-44 Vaccinated today till 8 pm

More than 23.8 lakh vaccine doses administered today

The cumulative number of COVID-19 vaccine doses administered in the country stands at 17,51,71,482 as per the 8 pm provisional report today.

4,74,629 beneficiaries of the age group 18-44 years received their first dose of COVID vaccine today and cumulatively 30,39,287 across 30 States/UTs since the start of Phase-3 of the vaccination drive.

As on Day-116 of the vaccination drive (11th May, 2021), total 23,85,092 vaccine doses were given. 10,65,634 beneficiaries were vaccinated for 1st dose and 13,19,458 beneficiaries received 2nd dose of vaccine as per the provisional report till 8 P.M. Final reports would be completed for the day by late tonight.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

US looking at joint production of Johnson and Johnson's COVID vaccine in India
The US is looking at joint production of Johnson and Johnson's COVID-19 vaccine in India and ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, the Charge D'Affaires of the US embassy, said on Tuesday. Smith also said that the efficacy of AstraZeneca.

Last month, the White House said that the US plans to share 60 million doses of AstraZeneca's vaccine globally as soon as they become available, and India expected a significant chunk of the total stockpile.

"I know that there are a number of doses of the AstraZeneca vaccine (with the US). They were manufactured in the US. They were manufactured at a plant outside of Baltimore but there were problems with this plant. So far the Food and Drug Administration of the US has not certified that these vaccines are available for anyone's use; for export or not," he said.

"So I cannot say when that will happen or what will be done exactly as we go forward on this," Smith said when asked whether the US was going to make available the AstraZeneca vaccine doses to India on an urgent basis.

He said the US was eager to supply the vaccine doses to the world but not before it is sure that they are safe and effective.

"Our development finance NSE 3.79 % cooperation is looking at how we can invest so that we can help produce the Johnson and Johnson's vaccine here in India. And I know that there are some private sector production talks that are underway from pharmaceutical companies to pharmaceutical companies," he said.

"I think we are watching carefully the production levels at the SII and elsewhere. We've been in close touch with the SII to try to determine what raw materials we could provide, and assistance that we can provide to help boost production," he said.
Last edited by Kakkaji on 11 May 2021 23:34, edited 1 time in total.
Atmavik
BRFite
Posts: 1987
Joined: 24 Aug 2016 04:43

Re: Wuhan Coronavirus Resource Thread

Post by Atmavik »

^^^ so our daily vaccination rate has dropped from 3.2 million to 2.x . I think it’s a combination of supply issues and 50 % going to states.

Supply should be sorted out by July/august hope logistics are also inline
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

The American AZ production issues are a collection of head-splitting complications. Emergent Biosolutions in Baltimore was a $630 million Operation Warp Speed recipient to produce vaccines. They were tasked with both J&J and AZ production in the US. The US backed 6 candidates in Op Warp Speed:
1. Novavax (reported yesterday that they're delaying seeking EUA because of production problems)
2. Pfizer-BioNTech
3. Moderna
4. J&J
5. Sanofi-GlaxoSmithKline
6. AstraZeneca

Sanofi failed and now license manufactures Moderna. J&J had a difficult history with the Baltimore plant, but at least has EUA (along with Pfizer and Moderna). Novavax is delayed. Astra Zeneca is not yet US approved.

J&J production was impacted because the Baltimore plant mixed AZ and J&J ingredients, destroying 20 million vaccines and putting another 60+ at risk of contamination: 62 million doses of Johnson & Johnson's vaccine need to be checked for contamination and may need to be thrown out, The New York Times reports .
FDA issues scathing report of Emergent plant responsible for contaminated Covid-19 vaccines

After multiple scaling problems and issues with contamination, Pfizer is slowly managing to hit higher volumes:
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
Amber G.
BRF Oldie
Posts: 9265
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

Thanks to IIT Kanpur - By popular demand: SUTRA site is up and running. It has the latest projection nicely presented at state, some districts, and metro area from DST sponsored super modeling team.
http://www.sutra-india.in/
Zynda
BRF Oldie
Posts: 2309
Joined: 07 Jan 2006 00:37
Location: J4

Re: Wuhan Coronavirus Resource Thread

Post by Zynda »

Delhi, Karnataka, Others Take Global Tender Route To Procure Covid Vaccine
New Delhi: Delhi, along with a bunch of southern Indian states, today joined several others in taking the global-tender route to procure COVID-19 vaccines even as domestic supply fails to keep up with rising demand. Uttar Pradesh, Maharashtra, and Odisha have already chosen this option amid the searing second wave of the pandemic.

The Centre says it's so far provided over 18 crore doses to states and Union Territories for free. They will receive 7,29,610 additional doses in the next three days.

"Over 90 lakh COVID Vaccine doses are still available with the states and Union Territories to be administered," the Union Health Ministry has said, according to a PTI report.

Yet, many states and Union Territories still face so much shortage that many are now prioritising recipients' second doses over the first so as to not lose the vaccine's efficacy.

"Till now, we had depended only on vaccines supplied by the Centre...Now, we have been instructed to float the tender and to complete the process within seven days," said Karnataka Deputy Chief Minister and State Covid Task Force head CN Ashwath Narayan.

His state will procure two crore doses to vaccinate those in the age group of 18-44 years.

Addressing a press conference today, Deputy Chief Minister Manish Sisodia even alleged that the BJP-ruled Centre was "forcing" state governments to invite global tenders.

"The Central government raised a question...why we haven''t passed a global tender to procure vaccines. The Centre already exported vaccines that could have been used in India, and is now sowing a discord among states," Mr Sisodia said.

"If states are asked to purchase vaccines internationally through global tenders, then the state with the largest coffers would unfairly procure the maximum number of doses. This will lead to fights among them..." he said.

In a letter written to the Centre, Chief Minister Arvind Kejriwal demanded that the vaccine formulae of Serum Institute's Covishield and Bharat Biotech's Covaxin be shared with other companies to scale up production.

Citing shortage, AAP leader Atishi Marlena had said that centres in Delhi where Covaxin was being administered to those in the 18-44 age group will have to be shut down after Tuesday evening if stocks weren't replenished.

Andhra Pradesh and Telangana are eyeing global tenders, too, for Covid vaccines. The Andhra government is set to float one in a day or two for doses from foreign manufacturers, according to state Principal Secretary (Health), Anil Kumar Singhal.

"We have already placed an order for purchase of Sputnik V vaccine but Dr Reddys Laboratories, the local manufacturer, said it will give clarity on supplies only after May 15 after assessing the production capacity," Mr Singhal said.

The foreign manufacturer has to secure the regulatory and statutory approvals from the Government of India, though. "Without that we cant administer the vaccine," Mr Singhal told PTI.

Uttar Pradesh has already flagged off the process for four crore doses. It may directly procure a large amount of vaccines like Sputnik V besides those developed by Moderna and Johnson & Johnson, PTI reported.

"It is felt that complete vaccination is the best way to protect precious lives of the people. Therefore, the Cabinet allowed the state government to go for global tender and get vaccines at the earliest," Odisha Chief Secretary SC Mohapatra said.

Every month, 50 percent of the total Central Drugs Laboratory (CDL) cleared vaccine doses of any manufacturer are procured by the Centre, while the remaining 50 per cent are for states and private establishments.

According to the Liberalised Pricing and Accelerated National COVID-19 Vaccination Strategy, COVID-19 vaccination is free at government vaccination centres that receive doses from the Centre for eligible population groups comprising healthcare workers, frontline workers and people above the 45 years of age.

However, states and private hospitals have to procure vaccines to immunise persons in the age group of 18 to 44 years.
As each day goes by criticism of vaccination strategy increases. At least in BLR, in month of May so far, 90% of private vaccination centers are lying idle. Further, there is a severe shortage of vaccines stock for people who want to take 2nd dose (as reflected in article)...people are waiting for 3+ hours in BBMP local wards or corporation hospitals to get their 2nd jab. Question is, where & how is the Centre allocating their 50% share?
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

On the global tender, what happens if the Chinese vendors quote the lowest price for Sinopharm? Will the GoI allow that import?

I doubt any other vendor will be able to supply at the price (Rs 300 per dose) that Covishield has been quoted as to the States.

The States will not be able to afford Pfizer or Moderna.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Indian double mutant variant of Covid-19 less severe for vaccinated: Study
The Indian double mutant variant of coronavirus — B.1.617 — that has been termed as a variant of concern by the World Health Organization is moderately resistant to antibodies and is highly transmissible but has low severity among those who are vaccinated, a molecular study has said.

The study published by Indian SARS-CoV-2 Genomic Consortia along with the scientists of the Cambridge University in the UK in the bioRxiv, an open access preprint server, “Extensive vaccination will likely protect against moderate to severe disease and will reduce the transmission of B.1.617 given the in vitro neutralisation data we and others have presented.”
rsingh
BRF Oldie
Posts: 4451
Joined: 19 Jan 2005 01:05
Location: Pindi
Contact:

Re: Wuhan Coronavirus Resource Thread

Post by rsingh »

Kakkaji wrote:India conducting 18-20 lakh COVID tests a day: ICMR
India is conducting 18-20 lakh tests for detection of COVID-19 per day, the ICMR chief said on Tuesday underlining that despite infection among laboratory staff, the test performance is still being maintained.
More test = more infected people found. Everybody wants vaccine at same time.
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

Kakkaji wrote:On the global tender, what happens if the Chinese vendors quote the lowest price for Sinopharm? Will the GoI allow that import?

I doubt any other vendor will be able to supply at the price (Rs 300 per dose) that Covishield has been quoted as to the States.

The States will not be able to afford Pfizer or Moderna.
All applicants still need to meet the accelerated pathway rules were published on April 15 2021. If they satisfy the requirements, the CDCSO will review their application within 3 working days and will have to conduct post approval bridging clinical trials within 30 days.

They also need to follow all the open price declarations and other requirements outlined in the 3rd Phase Policy Document published April 19 2021.

Skip the news. Read BOTH the documents above in detail. They are the original PIB reports.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Posting in full, as theer is a lot of good information:

Mutants affect the young too, but they hit the old harder: Balram Bhargava, ICMR
The variants circulating in India may be affecting the younger age group during the second wave, Balram Bhargava, director general, Indian Council of Medical Research (ICMR), said on Tuesday, a day after the World Health Organization (WHO) said that virus strain found in India is a variant of concern.

“The younger people are getting more involved because they have suddenly gone out and there are variants which may be affecting the younger people,” Bhargava said on Tuesday, asserting that the older population continues to remain vulnerable to the adverse outcome.

He said more than 70% patients in both waves are over 40 years and there is only a marginally higher proportion of younger patients.

“We have seen that during the first and second wave there is not much age difference,” he said. He added that people above 40 years are more vulnerable to the adverse outcome. Bhargava had earlier said that 70% of the patients in both the waves have been above 40 years and there is no difference in deaths among hospitalised patients in the two waves.


“There is no difference in deaths between the first and second wave among hospitalised patients. Further analysis into the death of admitted patients did not show any difference. It is 9.6% in hospitalised patients in the first wave and 9.7% among patients in the second wave,” he had said.

Experts have also seen prevalence of shortness of breath slightly higher in second wave of Covid-19 and symptoms like sore throat and dry cough were higher in the first wave. The Indian government on Tuesday said that India's national Covid-19 positivity rate is around 21%.
arshyam
BRF Oldie
Posts: 4570
Joined: 11 Aug 2016 06:14

Re: Wuhan Coronavirus Resource Thread

Post by arshyam »

@Suraj-san, your twitter thread is getting noticed, perhaps time for your next long form article? There are multiple states issuing global tenders and there will be a clamour for "why not Pfizer vaccine? the mudi shud rejine" etc. Some perspective in formats other that Twitter would definitely help with dissemination.


https://twitter.com/agrawalmanindra/sta ... 2985448448
Manindra Agrawal @agrawalmanindra
Very good analysis on logistics required for Pfizer vaccine.

Quote Tweet
Suraj @surajbrf · May 5
Recently various sources have pitched the Pfizer vaccine for India. This parlays the recent western ‘branding’ effort differentiating Pfizer, but it is known that this vaccine has some unique technical requirements.

This thread analyzes the Pfizer logistics in depth.

1/
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

arshyam
BRF Oldie
Posts: 4570
Joined: 11 Aug 2016 06:14

Re: Wuhan Coronavirus Resource Thread

Post by arshyam »

So despite all the feel good "everything is awesome" PR, nothing has changed on the ground (trying to reproduce the thread here for full ctx, but have shared the link for those who prefer reading on Twitter).

Should we really start to apply the squeeze on the lipid nanoparticles' export (link)? Perhaps that's the only language the US will understand.

https://twitter.com/natashaloder/status ... 1425133574 (she's an editor for The Economist)
Natasha Loder @natashaloder
So finally I have an answer to what has happened to Novavax production in India, thanks to the difficulty getting raw materials out of the US. The news was worse than I expected.

There is says, Stan Erck of that firm, a "global raw material supply difficulty".


Natasha Loder @natashaloder · May 2
So far the @WhiteHouse has ignored my question about the Novavax line.

As the crisis grows in India the worlds largest vaccine making company needs to be making as much vaccine as possible.

Meanwhile, we are getting distracted by discussions about IP


Natasha Loder @natashaloder · May 11 Replying to @natashaloder
Novavax lines in India and the UK have been affected by shortages of items needed from the US.

Start with the UK which has been manufacturing this vaccine for a while (not yet approved).

Novavax is struggling with 3 key things: biobags, media, and filters. @halhod


Natasha Loder @natashaloder · May 11
Novavax is doing its best to operate its lines at "full cadence". But when they have missing items the lines have to shut down.

For the UK they are "weeks" behind where they would have been had they had all the raw materials needed.

(FYI @RoryStewartUK)


Natasha Loder @natashaloder · May 11
Luckily, Britain is doing fine for vaccine.

Not so true in India, though. Here things are much grimmer.

Some will recall that on April 25th the @WhiteHouse said that it would send raw materials to make vaccines to India.
Statement by NSC Spokesperson Emily Horne on National Security Advisor Jake Sullivan’s Call with...
National Security Advisor Jake Sullivan spoke by phone today with National Security Advisor Ajit Doval, expressing deep sympathy for the people of India
whitehouse.gov


Natasha Loder @natashaloder · May 11
It was said that this move was to support the production of the AZ vaccine in India (Covisheild). Nothing was said about the Novavax line.

It seems pretty clear that the answer is no--the US did not send enough materials to fix the problems on that line.


Natasha Loder @natashaloder · May 11
According to Stan Erck, the @SerumInstIndia did not have enough supplies to keep both lines going at full capacity. It kept the AZ line going at maximum production, and the Novavax line at a smaller scale.


Natasha Loder @natashaloder · May 11
(That would support this article that suggests the Novavax line is running at 1/3 of capacity.)

The bottom line is that the firm has had to move its production forecasts back a *whole quarter*.
Serum chief flies to UK to escape 'threats' from CMs, corporates biggies
The level of expectation and aggression is unprecedented, says Poonawalla who's thinking of vaccine production overseas
telegraphindia.com


Natasha Loder @natashaloder · May 11
That vaccine is important for India, where people are dying at a rate of at least 3,500 a day, and for Covax.
Pouting face

Natasha Loder @natashaloder · May 11
More broadly it raises the question of how other new vaccine entrants (J&J, Curevac) are managing to obtain the ingredients they need to manufacture.

If we do not resolve these issues quickly how much this will dent the intention to produce 10-14bn doses? @Airfinity
@rasbech


Natasha Loder @natashaloder · May 11
The US argues the DPA isn't *causing* these problems there are just shortages of these items.

But firms say the DPA slows down exports, causes compensatory overstocking by other companies, and it disrupts supply chains.


Natasha Loder @natashaloder · May 11
And it isn't fair.

The US has plenty of vaccine.

The Pfizer vaccine relies on supplies from 19 different countries. What if those 19 countries decided they needed their own DPA in perpetuity? How would that work?


Natasha Loder @natashaloder · May 11
Firms also say things are worse under the current administration, not better.

Oh, and I have also heard of an un-named firm that had active substance in Europe, shipped to the US, and then were unable to get it out again.
Disappointed face

They had to improvise and find a new supply chain...


Natasha Loder @natashaloder · May 11
The US needs to become part of the solution, and stop being part of the problem.

When it moves to donate vaccine or support the global supply chains, other countries will follow and lives will be saved as a result.
arshyam
BRF Oldie
Posts: 4570
Joined: 11 Aug 2016 06:14

Re: Wuhan Coronavirus Resource Thread

Post by arshyam »

Suraj wrote:They already did that for me:
Pfizer Vaccine And Challenges Linked To Its Rollout In India
Ah, I missed this. I did look up your articles on Swarajya and didn't see anything related under your name.
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

arshyam wrote:
Suraj wrote:They already did that for me:
Pfizer Vaccine And Challenges Linked To Its Rollout In India
Ah, I missed this. I did look up your articles on Swarajya and didn't see anything related under your name.
Frankly I had no idea either until someone else pointed it out . Instead of chasing me around for an article they got someone else to write one and use my material. No complaints from me - I care only for the maximum number of people to understand these in detail instead of being a bunch of parrots peddling single point ‘narratives’ :)
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

Covaxin production will be doubled by May-June, says Centre
The current production capacity of Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-Aug 2021. It is expected to reach nearly 10 crore doses per month by Sep 2021: Ministry of Science & Technology
Financial support is being provided as a grant from GoI to the tune of appx Rs 65 Cr to Bharat Biotech’s new Bangalore facility. 3 public sectors companies are also being supported to increase the capacity of vaccine production: Ministry of Science & Technology (ANI)
https://www.financialexpress.com/lifest ... t/2249963/
chetonzz
BRFite
Posts: 138
Joined: 18 Mar 2019 11:11

Re: Wuhan Coronavirus Resource Thread

Post by chetonzz »

Honorable Milards keeping their useless gas emissions on

Image


they remind me of that funny guy from the movie "the Mummy"

https://www.youtube.com/watch?v=yUzxm1YDu0c
Sachin
Webmaster BR
Posts: 8965
Joined: 01 Jan 1970 05:30
Location: Undisclosed

Re: Wuhan Coronavirus Resource Thread

Post by Sachin »

Manas
BRFite -Trainee
Posts: 79
Joined: 01 Jan 1970 05:30

Re: Wuhan Coronavirus Resource Thread

Post by Manas »

While judicial activism is welcome in cases where systemic corruption or structural inefficiencies are impacting a common citizen's life the recent high and supreme court involvement, pronouncements on policy matters in the middle of a "once in a generation" crisis is a little disconcerting. Judiciary should recognize that they are a co-equal branch of govt and their job is to interpret the law and not to make policy from the bench.

Their siloed approach to "allocate xyz amount oxygen to this state", "you should have vaccinated this segment of the population several months ago" etc defies basic common sense and logic. At this rate one can rewind all the way back to summer 2019 (when presumably this leaked from WIV and infected the scientists experimenting with this virus and gain function research) and assert that "if Chinese scientists and communist party didnt do ABC then we would not have the pandemic" or if successive governments in India had invested $trillions on healthcare, water, power and other basic necessities since the 1950's then India would already have been a "developed, high income country". Their pronouncements are completely useless to help in the current situation other than providing ammunition to the opposition parties and the ill informed peanut gallery.

It is worrying to see this level of illogical ignorance on the part of the most learned judiciary that one expects more wisdom and judiciousness from !
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Bharat Biotech gets nod for phase 2/3 clinical trials of Covaxin on 2 to 18-year-olds
The Subject Expert Committee (SEC) under India’s drug regulator has given its nod to Bharat Biotech for conducting phase 2 and 3 clinical trials of its Covid-19 vaccine Covaxin on children aged between 2 to 18-year-old, a senior official told ET.

The trial is expected to be conducted on 525 subjects at various sites, including AIIMS-Delhi, AIIMS-Patna
.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Looks like the Russians may not be able to ride to India's rescue after all:

Mexico: Russia’s Sputnik V shortages mean limited 2nd doses
MEXICO CITY (AP) — Russian authorities have been having so many problems producing second doses of their Sputnik V coronavirus vaccine that Russia probably will be unable to supply enough to people who already got the first dose, Mexican officials said Monday.

It’s the latest account of production problems for Sputnik V, which the Russian government has been promising to other countries but has not been able to supply in sufficient quantities.

Sputnik is unusual among coronavirus vaccines in that the two doses are different and not interchangeable.

The Russian vaccine uses a modified version of the common cold-causing adenovirus to carry genes for the spike protein in the coronavirus as a way to prime the body to react if COVID-19 comes along.

That is a similar technology to the vaccine developed by AstraZeneca and Oxford University. But unlike AstraZeneca’s two-dose vaccine, the Russian approach uses a slightly different adenovirus for the second booster shot.

Mexico’s assistant health secretary, Hugo López-Gatell, said the Russians have found that the first adenovirus grows much more quickly than the second.

López-Gatell said Russian scientists are now suggesting abandoning the idea of giving the two separate Sputnik V shots several weeks apart and instead giving a second booster shot six months later.

“The comments made by Mexican authorities regarding the production of the second dose of the Sputnik V vaccine are not true,” the Fund’s press office said in a statement. “The manufacturing of both components of Sputnik V is being upscaled in Russia and abroad to fully meet the rising demand for the vaccine internationally.”

Mexico has so far received only 1.9 million Sputnik V doses, out of a total of 24 million it has signed a contract for. It has been forced to rely more on the Pfizer vaccine, of which it has received 10.6 million doses, as well as about 10 million doses of two Chinese vaccines. It also received about 4.6 million doses from AstraZeneca.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Some official announcements of production plans of Covishield and Covaxin:

Serum Institute says will raise monthly production to 10 crore doses by August, Bharat Biotech promises 7.8 crore
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday

The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.

Dr V Krishna Mohan, the Whole-time Director of Bharat Biotech, is learnt to have conveyed to the government that the production of Covaxin would be raised to 3.32 crore in July, and to 7.82 crore in August which will be maintained in September too.

Similarly, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India, has communicated that the production of Covishield would be ramped up to 10 crore doses each in August and will be maintained at that level in September, the official sources said.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Delhi receives 2.67 lakh more doses of Covishield; runs out of Covaxin stock: Atishi
AAP leader Atishi on Wednesday said Delhi received 2.67 lakh more doses of Covishield vaccine on May 11, but it has completely run out of Covaxin.

She said some Covaxin centres for the 18-44 age group have been temporarily shut from Wednesday.

"Around 16,000 Covaxin doses, which were available in the morning, were administered at 44 centres. These centres will also be shut after Wednesday evening," the AAP MLA said.

The AAP leader said the national capital received 2.67 lakh more doses of Covishield on Tuesday evening.

There are 4.18 lakh Covishield doses left for people in the 18-44 age group. These can last up to nine days, she added.

Delhi currently has four days of Covaxin and three days of Covishield stock for those above 45, and healthcare and frontline workers.


The AAP leader said 1.28 lakh doses were administered in the city on Tuesday.
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

Polio vaccine maker BIBCOL to manufacture 2 crore doses of Covaxin at UP's Bulandshahr plant every month
BIBCOL will manufacture 2 crore doses of Covaxin every month at its Bulandshahar plant in Uttar Pradesh.
The production to begin immediately
https://www.indiatvnews.com/news/india/ ... ine-704133
Tanaji
BRF Oldie
Posts: 4521
Joined: 21 Jun 2000 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Tanaji »

One thing I don’t understand: all states are going in for global tenders. We all know what the state of production is with various manufacturers. So why do the states think that they all get anything any faster than what local manufactures can provide after august when the production ramps up? Another point is do they really think they will get it cheaper than Rs 400?

I don’t quite follow the reasoning of this global tender…
Amber G.
BRF Oldie
Posts: 9265
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

Amber G. wrote:Thanks to IIT Kanpur - By popular demand: SUTRA site is up and running. It has the latest projection nicely presented at state, some districts, and metro area from DST sponsored super modeling team.
http://www.sutra-india.in/
Site is working quite well (there were few glitches but seem to be ironing out).
Looking at it and data:

- The drop in new infections continues! 7-day average plot is also showing a clear downturn.
Image
- It appears that we peaked 8th May. (Not bad - was predicted month ago as 5-11 May).
- Active Infections are also following the graph.
Image
nam
BRF Oldie
Posts: 4712
Joined: 05 Jan 2017 20:48

Re: Wuhan Coronavirus Resource Thread

Post by nam »

SII should drop the novavax adventure and instead make a deal with BB for Covaxin. It is blocking a large part of its production waiting for US to show attention.

ICMR now has tons of evidence on how single dose regime work for both vaccine. If there is low death and hospitalisation among single dose, infected people, I Mr should announce a large gap and go for maximum single dose.
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

nam wrote:SII should drop the novavax adventure and instead make a deal with BB for Covaxin. It is blocking a large part of its production waiting for US to show attention.

ICMR now has tons of evidence on how single dose regime work for both vaccine. If there is low death and hospitalisation among single dose, infected people, I Mr should announce a large gap and go for maximum single dose.
Covaxin is an inactivated vaccine needing high containment biosafety level 3 (BSL-3) facilities. SII doesn't have it, and Poonawalla mentioned last year they'll need to invest anywhere from Rs.300-600 cr to construct such facilities, which will also take a few months.
vijayk
BRF Oldie
Posts: 8785
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Post by vijayk »

Suraj wrote:
nam wrote:SII should drop the novavax adventure and instead make a deal with BB for Covaxin. It is blocking a large part of its production waiting for US to show attention.

ICMR now has tons of evidence on how single dose regime work for both vaccine. If there is low death and hospitalisation among single dose, infected people, I Mr should announce a large gap and go for maximum single dose.
Covaxin is an inactivated vaccine needing high containment biosafety level 3 (BSL-3) facilities. SII doesn't have it, and Poonawalla mentioned last year they'll need to invest anywhere from Rs.300-600 cr to construct such facilities, which will also take a few months.
They better start now ... Biden's team has no intent to help the world.
Post Reply